AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others
Several drugmakers, including Sandoz and Teva, are banking on swift approvals for their generic versions of the endometriosis drug Orilissa — but not if AbbVie can help it.
The pharma giant filed suit against the generic competitors in Delaware federal court on Thursday, asserting several patents, the latest of which expire in 2036. Plaintiffs argued in a 167-page complaint that abbreviated NDAs submitted by the defendants have caused or will lead to “foreseeable harm and injury” to AbbVie.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters